Individual biotechnology companies can not be expected to take responsibility.
Not exact matches
George Budwell (iShares Nasdaq
Biotechnology Index): Although the biotech industry is growing by leaps and bounds at the moment, the fact remains that
individual companies — and even titans of the industry like Gilead Sciences — are fraught with clinical, regulatory, and commercial risk.
For instance,
individuals at the North Carolina
Biotechnology Center were instrumental in identifying panelists and establishing contacts with
company representatives.
Since the summer of 1978
biotechnology has bestowed untold riches on
companies, institutions and
individual biologists.
This isn't to say the beginnings of personalized medicine haven't arrived — some
biotechnology companies already offer
individual DNA reports that provide people with information about disease risks and possible drug interactions based on a DNA sample [source: Pathway Genomics].
In this Q&A blog, I talk to an
individual who is on the front line of this revolution, Riley Doyle, CEO and Technical Lead at Desktop Genetics, a rapidly growing
biotechnology software
company based in London.